ATE236993T1 - Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper - Google Patents
Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörperInfo
- Publication number
- ATE236993T1 ATE236993T1 AT95938608T AT95938608T ATE236993T1 AT E236993 T1 ATE236993 T1 AT E236993T1 AT 95938608 T AT95938608 T AT 95938608T AT 95938608 T AT95938608 T AT 95938608T AT E236993 T1 ATE236993 T1 AT E236993T1
- Authority
- AT
- Austria
- Prior art keywords
- von willebrand
- willebrand factor
- monoclonal antibodies
- directed against
- antibodies directed
- Prior art date
Links
- 230000002785 anti-thrombosis Effects 0.000 title abstract 2
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
- 229960001134 von willebrand factor Drugs 0.000 title 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 3
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 abstract 1
- 108010081391 Ristocetin Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 abstract 1
- 229940034998 human von willebrand factor Drugs 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 229950004257 ristocetin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29707094 | 1994-11-30 | ||
| PCT/JP1995/002435 WO1996017078A1 (en) | 1994-11-30 | 1995-11-29 | Antithrombotic agent and anti-von willebrand factor monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE236993T1 true ATE236993T1 (de) | 2003-04-15 |
Family
ID=17841828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95938608T ATE236993T1 (de) | 1994-11-30 | 1995-11-29 | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US5916805A (de) |
| EP (1) | EP0795608B1 (de) |
| JP (1) | JP3331377B2 (de) |
| KR (1) | KR100406072B1 (de) |
| CN (1) | CN1254275C (de) |
| AT (1) | ATE236993T1 (de) |
| DE (1) | DE69530316T2 (de) |
| DK (1) | DK0795608T3 (de) |
| ES (1) | ES2197210T3 (de) |
| FI (1) | FI119734B (de) |
| NO (1) | NO319738B1 (de) |
| PT (1) | PT795608E (de) |
| WO (1) | WO1996017078A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE236993T1 (de) | 1994-11-30 | 2003-04-15 | Ajinomoto Kk | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6228360B1 (en) | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
| CA2344606A1 (en) * | 1998-10-23 | 2000-05-04 | Huabing Yuan | Conformation-specific anti-von willebrand factor antibodies |
| CN1198198C (zh) * | 2001-02-27 | 2005-04-20 | 索尼公司 | 字符输入方法及字符输入装置 |
| JP2005298336A (ja) * | 2002-01-29 | 2005-10-27 | Ajinomoto Co Inc | 炎症性疾患治療用薬剤 |
| JPWO2004011030A1 (ja) * | 2002-07-29 | 2005-11-24 | 味の素株式会社 | 血小板減少症治療用医薬組成物 |
| US20050136056A1 (en) * | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
| ATE512364T1 (de) * | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
| JP2006520584A (ja) * | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| AU2003286004A1 (en) * | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| ES2551682T3 (es) * | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| NZ576284A (en) * | 2003-01-10 | 2010-07-30 | Ablynx Nv | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| WO2004062551A2 (en) | 2003-01-10 | 2004-07-29 | Ablynx N.V. | RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| CN1323713C (zh) * | 2003-07-07 | 2007-07-04 | 张新侯 | 可溶性p－选择素及炭疽致死毒素的新用途 |
| KR20070101227A (ko) | 2004-09-07 | 2007-10-16 | 아케믹스 코포레이션 | 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도 |
| US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| WO2006029258A2 (en) * | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
| PT1836500E (pt) | 2005-01-14 | 2010-09-28 | Ablynx Nv | Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas |
| KR101414438B1 (ko) * | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체 |
| EP1918302A3 (de) * | 2006-05-18 | 2009-11-18 | AvantGen, Inc. | Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern |
| JP5505853B2 (ja) | 2007-02-13 | 2014-05-28 | 味の素株式会社 | 微酸性アルギニンを添加剤とするウイルス不活化法 |
| US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| JP2011518772A (ja) * | 2008-03-21 | 2011-06-30 | アブリンクス エン．ヴェー． | フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法 |
| CN102089319B (zh) | 2008-05-08 | 2013-11-13 | 味之素株式会社 | 蛋白质的重折叠方法 |
| CN102532316B (zh) * | 2010-12-24 | 2014-06-18 | 神州细胞工程有限公司 | 一种抗vWF单克隆抗体及其应用 |
| CN103608463A (zh) | 2011-06-23 | 2014-02-26 | 味之素株式会社 | 由使具有免疫球蛋白折叠结构的蛋白和能够形成亚单元结构的蛋白融合而得到的单体蛋白组成的多聚体蛋白的制备方法 |
| WO2015095426A1 (en) * | 2013-12-18 | 2015-06-25 | Siemens Healthcare Diagnostics Inc. | Detection of endothelial disease |
| EP3131929B1 (de) * | 2014-04-16 | 2022-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antikörper zur prophylaxe oder behandlung von blutungsepisoden |
| US20220380478A1 (en) | 2019-07-01 | 2022-12-01 | Tonix Pharma Holdings Limited | Anti-cd154 antibodies and uses thereof |
| WO2021118845A1 (en) * | 2019-12-12 | 2021-06-17 | Corning Incorporated | Light-diffusing element configured to affect thrombi formation on intravenous catheter |
| EP4274587A1 (de) | 2021-01-06 | 2023-11-15 | Tonix Pharma Limited | Verfahren zur induzierung von immuntoleranz mit modifizierten anti-cd154-antikörpern |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202264A (en) * | 1989-10-27 | 1993-04-13 | Health Research, Incorporated | ELISA using multi-species antibodies for detection of von Willebrand factor in multiple species |
| US5342830A (en) * | 1990-11-16 | 1994-08-30 | Cor Therapeutics, Inc. | Antithrombosis agents |
| ATE236993T1 (de) * | 1994-11-30 | 2003-04-15 | Ajinomoto Kk | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper |
| AU724579B2 (en) | 1996-04-01 | 2000-09-28 | Sankyo Company Limited | Anti-Fas recombinant antibodies and DNA therefor |
-
1995
- 1995-11-29 AT AT95938608T patent/ATE236993T1/de active
- 1995-11-29 PT PT95938608T patent/PT795608E/pt unknown
- 1995-11-29 CN CNB951974742A patent/CN1254275C/zh not_active Expired - Fee Related
- 1995-11-29 WO PCT/JP1995/002435 patent/WO1996017078A1/ja not_active Ceased
- 1995-11-29 JP JP51858396A patent/JP3331377B2/ja not_active Expired - Fee Related
- 1995-11-29 DE DE69530316T patent/DE69530316T2/de not_active Expired - Lifetime
- 1995-11-29 US US08/836,982 patent/US5916805A/en not_active Expired - Lifetime
- 1995-11-29 KR KR1019970703619A patent/KR100406072B1/ko not_active Expired - Fee Related
- 1995-11-29 DK DK95938608T patent/DK0795608T3/da active
- 1995-11-29 ES ES95938608T patent/ES2197210T3/es not_active Expired - Lifetime
- 1995-11-29 EP EP95938608A patent/EP0795608B1/de not_active Expired - Lifetime
-
1997
- 1997-05-16 NO NO19972253A patent/NO319738B1/no not_active IP Right Cessation
- 1997-05-29 FI FI972279A patent/FI119734B/fi not_active IP Right Cessation
-
1999
- 1999-04-26 US US09/299,016 patent/US6280731B1/en not_active Expired - Lifetime
-
2001
- 2001-08-08 US US09/923,952 patent/US6793920B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT795608E (pt) | 2003-08-29 |
| CN1174575A (zh) | 1998-02-25 |
| US6793920B2 (en) | 2004-09-21 |
| KR100406072B1 (ko) | 2004-03-30 |
| FI119734B (fi) | 2009-02-27 |
| FI972279A0 (fi) | 1997-05-29 |
| NO319738B1 (no) | 2005-09-12 |
| NO972253D0 (no) | 1997-05-16 |
| EP0795608A4 (de) | 2001-11-28 |
| WO1996017078A1 (en) | 1996-06-06 |
| EP0795608A1 (de) | 1997-09-17 |
| DK0795608T3 (da) | 2003-07-21 |
| DE69530316D1 (de) | 2003-05-15 |
| CN1254275C (zh) | 2006-05-03 |
| ES2197210T3 (es) | 2004-01-01 |
| EP0795608B1 (de) | 2003-04-09 |
| DE69530316T2 (de) | 2004-02-12 |
| US5916805A (en) | 1999-06-29 |
| JP3331377B2 (ja) | 2002-10-07 |
| NO972253L (no) | 1997-07-29 |
| FI972279L (fi) | 1997-07-29 |
| US20020028204A1 (en) | 2002-03-07 |
| US6280731B1 (en) | 2001-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE236993T1 (de) | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper | |
| RU94046294A (ru) | Стероидные гликозиды для лечения гиперхолестеринэмии | |
| ES2182357T3 (es) | Nueva utilizacion de budesonide y formoterol. | |
| MX9204268A (es) | Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma. | |
| EA200101156A1 (ru) | ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ | |
| DE69738000D1 (de) | Neue Arzneiformulierung enthaltend Budesonide | |
| BR9406025A (pt) | Composição para barbear não de aerossol | |
| FI925098A7 (fi) | Ihmisen papilloomavirusten 1,5,6,8,11,16,18,31,33 ja 56 synteettisiä p eptidejä, jotka ovat käyttökelpoisia immunoanalyysissä diagnostisiin t arkoituksiin | |
| ATE283704T1 (de) | Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom | |
| IT1281188B1 (it) | Composizione per prevenire e trattare infiammazioni con immunoglobulina a. | |
| SE9401540D0 (sv) | Munhygienkomposition | |
| BR9509975A (pt) | Formulação farmacêutica | |
| DE60237447D1 (de) | Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel | |
| SE9402880D0 (sv) | New peptide derivatives | |
| ATE188692T1 (de) | Fibrinogenrezeptorantagonisten | |
| KR930019224A (ko) | 유산 위험 치료제 | |
| TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. | |
| DE59101404D1 (de) | Topische Präparate. | |
| FI883723A7 (fi) | Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan | |
| FR2714603B1 (fr) | Composition dermatologique et son utilisation pour la préparation d'un médicament. | |
| CA2206423A1 (en) | Antithrombotic agent and anti-von willebrand factor monoclonal antibodies | |
| DK0663832T3 (da) | Anvendelse af 4'-iod-4'-deoxydoxorubicin til behandling af amyloidose | |
| DE59107240D1 (de) | Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung | |
| SE9401596D0 (sv) | New compounds | |
| FR2601950B1 (fr) | N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0795608 Country of ref document: EP |